The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000675325
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
5/03/2026
Date registered
Help: Date registered
5/06/2026
Date last updated
Help: Date last updated
5/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
5/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Testing if a digital health enhanced model of type 2 diabetes care can be implemented in general practice settings for people with type 2 diabetes in Inala, Queensland, Australia.
Scientific title
A pilot hybrid type 3 implementation trial of an eHealth-enhanced model of type 2 diabetes care called ‘Rethinking the model of care for diabetes using eHealth (REMODeL)’ within a general practitioner-led type 2 diabetes-specific clinic in an urban primary care setting in Inala, Queensland, Australia to understand the factors which affect its successful implementation.
Additional trial identifiers [1] 316708 0
Nil
Universal Trial Number (UTN)
Trial acronym
REMODeL REIMCD
Related trial records

Health condition
Health condition(s) studied:
Diabetes 340960 0
Condition category
Condition code
Metabolic and Endocrine 337107 337107 0 0
Diabetes
Public Health 337554 337554 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The REMODeL ReIMCD project is a pilot implementation trial which adapts the successful REMODeL program originally designed for hospital outpatient settings. REMODeL is an eHealth-enhanced model of diabetes care that will be adapted for general practice settings through a previous study which co-designed the adaptations with general practitioners and people with diabetes receiving diabetes care in general practice settings. REMODeL integrates a commercially available digital diabetes management system called Health2Sync. The intervention enables patients to track their physical activity, nutrition, sleep and blood glucose using a wirelessly connected meter, receive personalised and contextually relevant self-management feedback and prompts via the Health2Sync app (participants will have the control to disable prompts if they wish), and share data seamlessly with clinicians, who can view results through a secure dashboard to support timely review, risk mitigation, and goal setting within routine care pathways.

Examples of self-management feedback and prompts are as follows:
“Hi {first_name}, thanks for downloading Health2Sync! We noticed you haven't entered any records yet. All you need to do is to tap the "+" button to begin! Try it out and you'll see how Health2Sync can help you!” – sent once only if participant has not entered or synchronised any measurements or entered data after installing.

“You’re on the right track. Keep going!” – if participant has at least 2 readings within set target blood glucose range; sent once a week.

“Hi {first_name}, great job sticking to your measurement plan! Keep up the good work!” – if participant follows their set self-measurement activities (e.g. blood glucose measurements) as per care plan set with clinician; at most once a week.
Examples of self-management goals (examples only, these are set with clinicians as part of care planning):
Blood glucose before meals: 4 – 7 mmol/L
Blood glucose after meals: 5 – 10 mmol/L
Regular blood glucose monitoring frequency: after waking up in the morning, 5min before any meals, 2 hrs after meals.

For the 3-month study participation duration, participants of this trial will have access to and be asked to interact with Health2Sync based on their own preferences and diabetes self-management goals developed with the advice of clinicians at the trial site. Health2Sync can also facilitate clinician feedback via the app should there be updates to self-management needs or the clinician would like a check-in (e.g. the clinician has received any filtered pre-set clinical alerts). The research team will also assess and monitor app utilisation based on app use analytics.
For clinicians, they have previously, in a separate study, codesigned how the use of Health2Sync fits into their current clinic workflow.

An assigned clinician (e.g. credentialed diabetes educator) will be responsible for monitoring the Health2Sync clinician dashboard regularly (at least twice a week) for customised alerts and any participant communication (can be via the messaging function in the Health2Sync app, a phone call from the clinic or in-person at the clinic as required), however this clinician can informally do it more regularly as their work allows. Other clinicians, in this study they will be doctors (general practitioners and endocrinologists), at the clinic can access Health2Sync as needed and how often and when they access Health2Sync is one of our implementation trial outcome measures. At onboarding for participants with diabetes, clinicians will set self-management goals and other relevant care parameters into Health2Sync. Clinicians interact with participants virtually between any of their routine appointments or appointments where the participant is recalled to the clinic for any clinically relevant reason.

All participants with diabetes joining the trial will undertake an approximately 3-week long ‘run-in’ period. The run-in period serves the purpose of (1) ensuring participants are given the opportunity to become familiar with the new technology; (2) enable participants time to ask questions and troubleshoot any problems with the technology; (3) ensure participants are willing to continue using the technology. If participants are unable to successfully complete the run-in period (i.e. comfortably use the technology), we will note, qualitatively, the factors that lead to run-in failure.

This implementation aims to assess feasibility and generate practical insights for scaling an integrated, person-centred digital model of diabetes care across urban primary care settings.
Intervention code [1] 333392 0
Treatment: Devices
Intervention code [2] 333393 0
Behaviour
Description of the comparator or control
No control with the comparator being baseline measures at time of onboarding.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344630 0
Reach of the model of care
Timepoint [1] 344630 0
Trial completion (i.e. once the final trial participant has concluded all trial tasks or withdraws or deemed to be lost to follow up as per protocol), approximately 6 months from trial commencement.
Primary outcome [2] 344631 0
Acceptability - acceptability of technology to people with diabetes
Timepoint [2] 344631 0
3 months from participant’s enrolment date
Primary outcome [3] 344632 0
Feasibility of the model of care
Timepoint [3] 344632 0
3 months from participant’s enrolment date
Secondary outcome [1] 458678 0
[Primary Outcome 4] Acceptability - clinician acceptability of model of care
Timepoint [1] 458678 0
End of trial (i.e. after final participant has completed study activities, withdrawn or considered lost to follow up as defined in study protocol).
Secondary outcome [2] 458687 0
Effectiveness - diabetes self management
Timepoint [2] 458687 0
Baseline (at enrolment) and 3 months from participant’s enrolment date
Secondary outcome [3] 458688 0
Effectiveness - number of hypoglycaemic event
Timepoint [3] 458688 0
Baseline (at enrolment) and 3 months from participant’s enrolment date
Secondary outcome [4] 458689 0
Effectiveness - diabetes distress
Timepoint [4] 458689 0
Baseline (at enrolment) and 3 months from participant’s enrolment date
Secondary outcome [5] 460822 0
Effectiveness - glycaemic control
Timepoint [5] 460822 0
Baseline (at enrolment) and 3 months from participant’s enrolment date
Secondary outcome [6] 460823 0
Effectiveness - blood pressure control
Timepoint [6] 460823 0
Baseline (at enrolment) and 3 months from participant’s enrolment date
Secondary outcome [7] 460824 0
Effectiveness - body weight
Timepoint [7] 460824 0
Baseline (at enrolment) and 3 months from participant’s enrolment date
Secondary outcome [8] 460825 0
Adoption (people with diabetes)
Timepoint [8] 460825 0
3 months from participant’s enrolment date
Secondary outcome [9] 460826 0
Implementation (people with diabetes)
Timepoint [9] 460826 0
End of trial (i.e. after final participant has completed study activities, withdrawn or considered lost to follow up as defined in protocol)
Secondary outcome [10] 460827 0
Implementation (clinicians)
Timepoint [10] 460827 0
End of trial (i.e. after final participant has completed study activities, withdrawn or considered lost to follow up as defined in protocol)
Secondary outcome [11] 460828 0
Maintenance - frequency of app use by clinicians
Timepoint [11] 460828 0
End of trial (i.e. after final participant has completed study activities, withdrawn or considered lost to follow up as defined in protocol)
Secondary outcome [12] 460829 0
Maintenance - frequency of app use by people with diabetes
Timepoint [12] 460829 0
End of trial (i.e. after final participant has completed study activities, withdrawn or considered lost to follow up as defined in protocol)
Secondary outcome [13] 460830 0
Maintenance - frequency of system faults or errors preventing normal system use
Timepoint [13] 460830 0
End of trial (i.e. after final participant has completed study activities, withdrawn or considered lost to follow up as defined in protocol)
Secondary outcome [14] 461143 0
Effectiveness - body mass index (BMI)
Timepoint [14] 461143 0
Baseline (at enrolment) and 3 months from participant’s enrolment date

Eligibility
Key inclusion criteria
• Be aged 18 years or older
• Have a diagnosis of type 2 diabetes mellitus (T2DM) for at least 6 months.
• Be a current patient attending the BSCDS clinic site within IPC.
• Be identified by their GP (regular GP and/or beacon clinic GP), endocrinologist, nurse or credentialled diabetes educator as having sub-optimally controlled T2DM, defined as HbA1c greater or equal to 8.0% measured within the last 2 months and diagnosis of T2DM for at least 6 months.
• Have access to a smartphone (iOS or Android).
• Be able to provide informed consent.
• Be able to complete the 3-week run-in period, including consent, onboarding, and attendance at the Week 3 baseline appointment.
• Be willing to use a continuous glucose monitor (CGM) for the first two weeks, and a supplied Bluetooth-enabled BGL meter thereafter, unless their smartphone is incompatible. If their smartphone is incompatible, they will be asked to use the BGL meter only for the duration of the study.
• If unable to use CGM due to technical limitations, be willing to use the supplied Bluetooth-enabled BGL meter instead.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
· Have type 1 diabetes, gestational diabetes, or another form of diabetes.
· Are currently participating in another intervention study for diabetes management.
· Are unable to communicate in English or require a translator, unless culturally appropriate support can be provided.
· Have cognitive impairment or a medical/psychiatric condition that may affect their ability to provide informed consent or engage with the intervention.
· Are pregnant or planning pregnancy during the study period. This will be self-reported.
· Have no stable internet access and are unable to access or use a compatible mobile device.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD

Funding & Sponsors
Funding source category [1] 321235 0
Government body
Name [1] 321235 0
Metro South Health
Country [1] 321235 0
Australia
Primary sponsor type
Government body
Name
Metro South Health
Address
Country
Australia
Secondary sponsor category [1] 323942 0
None
Name [1] 323942 0
Address [1] 323942 0
Country [1] 323942 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319762 0
Metro South Human Research Ethics Committee
Ethics committee address [1] 319762 0
Ethics committee country [1] 319762 0
Australia
Date submitted for ethics approval [1] 319762 0
05/09/2025
Approval date [1] 319762 0
08/09/2025
Ethics approval number [1] 319762 0
HREC/2025/QMS/119612

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148314 0
Dr Anish Menon
Address 148314 0
Princess Alexandra Hospital 199 Ipswich Road Woolloongabba, QLD 4102
Country 148314 0
Australia
Phone 148314 0
+61401409585
Fax 148314 0
Email 148314 0
Contact person for public queries
Name 148315 0
Anish Menon
Address 148315 0
Princess Alexandra Hospital 199 Ipswich Road Woolloongabba, QLD 4102
Country 148315 0
Australia
Phone 148315 0
+61401409585
Fax 148315 0
Email 148315 0
Contact person for scientific queries
Name 148316 0
Anish Menon
Address 148316 0
Princess Alexandra Hospital 199 Ipswich Road Woolloongabba, QLD 4102
Country 148316 0
Australia
Phone 148316 0
+61401409585
Fax 148316 0
Email 148316 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: This is a pilot study composed of 50 individuals. With such a small sample at a single-site, the risk to privacy is too high since we might not be able to guarantee fully de-identifiable data.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.